To the Mitochondria Review Policy Team, HFEA:

We are writing in response to the "Call for evidence: Update to scientific review of the methods to avoid mitochondrial disease." As you know, the US Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee Meeting held a public meeting about these proposed methods on February 25-26, 2014.

The FDA’s 35-page briefing document about the scientific, technologic, and clinical issues related to what it terms “mitochondrial manipulation technologies” previews some of the issues that were discussed at the meeting. The document notes that “the full spectrum of risks... has yet to be identified,” and offers a list of known safety concerns regarding both the women involved and the potential resulting children. These include damage caused to the egg or embryo by the manipulations, nuclear-mitochondrial incompatibility, epigenetic modification of nuclear DNA, and the impact of the chemicals and drugs used at various points throughout the procedure.

Further, the briefing document states that none of the existing data, which it terms “preliminary evidence,” should be seen as traditional proof-of-concept studies because with one exception, none of the studies used eggs or embryos containing abnormal mitochondria. In other words, the studies were not conducted with models of mitochondrial disease. Because of this, the document states, “it is not clear whether these data provide any support for the potential effectiveness of these methods in humans.”

In some eleven and a half hours of presentations and deliberations on February 25 and 26, the committee members heard and discussed these and other serious concerns about the safety and efficacy of pro-nuclear transfer, maternal spindle transfer, and related oocyte and embryo modification techniques. Some of these concerns involved the inadequacy of the preclinical evidence that has been presented to date, both in animal models and in vitro. Some addressed the insufficient understanding of the basic science of mitochondrial disease and of the methods under consideration. Some applied to the daunting challenges of designing meaningful clinical trials, or indeed of safe clinical trials since pregnancy itself poses serious health risks for many women with mitochondrial diseases.
In his summary statement after the first day’s session, committee chair Dr. Evan Y. Snyder noted that although some committee members found the preclinical data intriguing,

“There was a sense of the committee that at this particular point in time there is probably not enough data either in animals or in vitro to conclusively move on to human trials without...answering a few additional questions.....The concerns revolved around the preclinical data with regard to fundamental translation, but also with regard to the basic science” [transcribed from the meeting video, posted here].

We urge you to carefully examine and thoroughly review and follow up on the wide range of safety and efficacy concerns raised by the FDA committee, and by others, in order to fulfill your mandate of providing an accurate summary of the current state of expert and scientific understanding.

We also draw your attention to the fact that the phrase “mitochondrial replacement techniques” used in your Terms of Reference paragraph is misleading: no mitochondria are replaced in pro-nuclear and maternal spindle transfer protocols, which instead replace the nuclear genome of an egg. We therefore urge that you avoid this formulation, which has the effect of minimizing the magnitude of the manipulations, in future documents.

In addition, we note the very short time that was provided for responses to the “Call for evidence,” and we request that you extend the deadline in order to allow others to communicate their concerns.

Sincerely,

Marcy Darnovsky, PhD, Executive Director, Center for Genetics and Society
Enola G. Aird, Mothers for a Human Future*
Joan Almon, Co-founder, U.S. Alliance for Childhood
Lisa Archer, Director, Food and Technology Program, Friends of the Earth
Françoise Baylis, PhD, FRSC, FCAHS, Professor and Canada Research Chair in Bioethics and Philosophy, Faculty of Medicine, Dalhousie University
Diane Beeson, PhD, Associate Director, Alliance for Humane Biotechnology
Philip L. Bereano, Professor Emeritus, Technology and Public Policy, University of Washington
Deborah A. Bolnick, PhD, Assistant Professor, Department of Anthropology, University of Texas at Austin*
Charisse Carney-Nunes, Washington, DC
Christopher Clouder, Alliance for Childhood
Francine Coeytaux, MPH, Pro-Choice Alliance for Responsible Research
Gwen D'Arcangelis, PhD, Assistant Professor, Interdisciplinary General Education, California State Polytechnic University*
Donna Dickenson, PhD, Emeritus Professor of Medical Ethics and Humanities, University of London*
Troy Duster, PhD, Chancellor’s Professor & Senior Fellow, Warren Institute on Law and Social Policy, Boalt School of Law, University of California, Berkeley*
Jill Escher, Escher Fund for Autism
Hedva Eyal, Isha I’Isha, Haifa Feminist Center
Susan Fogel, J.D., Pro-Choice Alliance for Responsible Research
Alexander Gaguine, President, Appleton Foundation
Debra Greenfield, J.D., Adjunct Assistant Professor, UCLA Institute for Society & Genetics*
Rosann Greenspan, PhD, Executive Director, Center for the Study of Law and Society, University of California, Berkeley*
Jaydee Hanson, Program Director for Human Genetics, International Center for Technology Assessment
Richard Hayes, PhD, Visiting Scholar, College of Natural Resources, University of California, Berkeley
Geoffrey Hunt, BSc (Hons) Mlitt PhD, Professional Fellow of Institute of Nanotechnology, UK; Director, Centre for Bioethics & Emerging Technologies, St Mary's University
Patricia Jennings, PhD, Chair, Sociology & Social Services, California State University, East Bay
David Albert Jones, MA (Cantab), MA, MSt, DPhil (Oxon), Director, The Anscombe Bioethics Centre, Oxford; Research Fellow, Blackfriars Hall, Oxford; Visiting Professor, St Mary's University, Twickenham
Jonathan Kahn, J.D., PhD, Professor, Hamline University School of Law*
Ulrike Kloeppel, Gen-ethisches Netzwerk
Mariana Leal Ferreira, PhD, Professor of Liberal Studies; Co-Director, Global Peace, Human Rights & Justice Studies, San Francisco State University*
Trudo Lemmens, D.C.L., Scholl Chair in Health Law and Policy, University of Toronto
Abby Lippman, PhD, Professor Emerita, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University
Prof.Dr. rer.nat. Calum MacKellar, Director of Research, Scottish Council on Human Bioethics
Gina Maranto, Director, Ecosystem Science and Policy, University of Miami
Michiel Matthes, Secretary-General, Alliance for Childhood European Network Group
Steve May, Executive Director, Forum on Genetic Equity
Shree Mulay, PhD, Associate Dean, Faculty of Medicine, Memorial University
Stuart Newman, PhD, Professor of Cell Biology and Anatomy, New York Medical College
Peggy O'Mara, Editor and Publisher, peggyomara.com
Osagie Obasogie, J.D., PhD, Professor of Law, University of California, Hastings College of Law
Milton Reynolds, Board Chair, Literacy for Environmental Justice
Dorothy Roberts, J.D. , University of Pennsylvania
James J. Rusthoven, MD, MHSc(bioethics), PhD, Professor of Oncology, McMaster University
Susanne Schultz, Gen-ethisches Netzwerk
Carmel Shalev, J.D., PhD, Department for Reproduction and Society, International Center for Health, Law and Ethics, Haifa University
Pete Shanks, Writer, Biopolitical Times*
Stephen Shmanske, PhD, Emeritus Professor of Economics, California State University, East Bay
Evelyne Shuster, PhD, Research Ethics, Office of the Chief of Staff, Philadelphia Veterans Affairs Medical Center
Emily Smith Beitiks, PhD, Assistant Director, Paul K. Longmore Institute on Disability, San Francisco State University*
M. L. Tina Stevens, PhD, Director, Alliance for Humane Biotechnology
Charis Thompson, PhD, Professor, University of California at Berkeley and London School of Economics
Sheila R. Tully, PhD, San Francisco State University*
Alexander von Schwerin, Gen-ethisches Netzwerk
Uta Wagenmann, Gen-ethisches Netzwerk
David Winickoff, J.D., Professor, Department of Environmental Science, Policy and Management, University of California at Berkeley

* Institutional affiliations for identification purposes only